Cigna pitches five-year plan with fee cuts, pharmacy pass-through and behavioral-health capitation to Hillsborough County evaluators

Cigna representatives presented their proposal for Hillsborough County’s self-funded group health plan (RFP 24-2491) to the county’s evaluation committee in a virtual procurement meeting, outlining a five‑year pricing structure, pharmacy pricing changes and expanded behavioral‑health services.

The proposal, delivered by Christine Castellvi, Market President for Cigna Healthcare, and members of her team, emphasized cost containment and expanded services. “You’ve been a client of ours since 2014,” Castellvi said, describing a long relationship the company said informed its offer and investments for the next contract period.

Cigna’s written and oral highlights included a 3% reduction in fees compared with current charges, with those fees held flat for five years; a pharmacy pricing model described as a transparent pass‑through called ClearChoice Rx; and performance guarantees with more than 70% of ASOPs (administrative/service operational performance standards) placed at risk with financial consequences for nonperformance.

Ben Heugel, National Account Executive for Cigna, summarized the pricing change: “Our fees were positioned 3% lower than they are currently,” and said the reduction would be maintained for five years. Bart Berg, the presenter on pharmacy, described the pass‑through approach and administration fee: “The admin fee is a low $3.95 per prescription,” and Cigna said it would pass through 100% of manufacturer rebates rather than keeping a spread on drug pricing. Cigna estimated the county would receive about $1.7 million more in rebates in year one under the proposal and more than $35 million in rebates over three years.

On network access and contracting, Dennis May, Assistant Vice President of Provider Network Management, told the committee the company had recently renegotiated a large set of local provider contracts and reported no interruptions to network access during that process: “We had no interruption to our network access in the commercial medical space,” May said, and Cigna said those multi‑year renewals improved its discount position. The presentation included a network discount repricing cited at 68.2%.

Cigna proposed a $2,000,000 client fund that the county could allocate toward on‑site resources, employee medical center services, EAP buyups, and a minimum commitment to MW/DBE vendors as part of the funded options. Presenters said Hillsborough County could keep its existing four on‑site staff or reallocate dollars to add or change services using that fund.

Behavioral health was a particular focus. Presenters described a capitated behavioral‑health option in which Cigna would carry the risk and guarantee provider availability and access modalities (telehealth, video, in‑person and messaging). A Cigna speaker said behavioral health utilization has been rising and that members with behavioral health comorbidities typically generate higher total cost of care; Cigna said the capitation rate will be adjusted annually and that Cigna would assume the financial risk under the capitation arrangement.

Committee members pressed for clarifications in the question‑and‑answer session. One committee member asked whether behavioral‑health capitation would create a new per‑member‑per‑month (PMPM) charge; presenters said the capitation is already reflected in the county’s RFP response and that detailed PMPM figures had been provided in Cigna’s RFP submission. When asked about the county’s financial exposure, presenters said Cigna carries the capitation risk and that capitation is subject to annual adjustments similar to other health‑care costs.

On specialty drugs and novel therapies, Cigna described an “Embark” protection benefit for gene therapies that the company said pools client dollars (quoted in the presentation at about $0.99 per member per month) to pay catastrophic gene‑therapy costs; presenters said surpluses in that pool have been returned to participating employers in past years and that members’ out‑of‑pocket cost for therapies in the pool would be zero. Cigna noted developers are releasing additional gene therapies and characterized the protection benefit as a way to socialize low‑probability, very high‑cost claims.

The committee also asked about biologic and biosimilar strategy for high‑cost specialty drugs such as Humira and Stelara. Cigna said it currently lists some biosimilars as co‑preferred with originator brands and plans to guide new therapy starts toward biosimilars beginning in 2025, while allowing medical‑necessity exceptions and offering to strategize implementation with the county.

Cigna emphasized digital and member engagement tools, saying Hillsborough County’s registration rate for myCigna is about 88%—above an industry baseline of 80%—and described integrated digital navigation, a client‑specific toll‑free number, and other consumer tools to help members access benefits. Presenters said Cigna’s combined clinical, pharmacy and digital approach had produced $150 million in cumulative savings for the county since 2014, with an average annual trend of 3.4% and $18.7 million in savings recorded in 2023.

No formal procurement vote or committee decision was taken during the presentation. Committee members indicated they would review the written RFP responses and financial exhibits (Cigna said detailed pricing and capitation PMPMs were provided in its RFP submission) as part of the evaluation process. The recorded vendor presentation and question‑and‑answer session will be available under the procurement process’ public records procedures, and the committee moved to close the meeting at the end of the scheduled time.

What the committee asked for but did not receive in the presentation were implementation timelines and an explicit contract award recommendation; those items remain for subsequent procurement evaluation and negotiation.